A Phase 2 interventional study of capecitabine [Xeloda] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 76 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 107th largest by enrollment of the 183 interventional ones that give a count, is one of 16 that started in 2008, is one of 110 in phase 2, and was the 108th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–70
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 40 · Phase 4 5
First in 1998; this study’s year is marked. 16 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 50 across the 183 interventional studies. Of the 134 that completed or were terminated, 35 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 206 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 61st largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2008, is one of 32 in phase 2, and was the 27th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
4 of the studies testing oxaliplatin in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-weekly cycles of treatment with either: 1) Xeloda, Avastin and oxaliplatin; or 2) Xeloda, Avastin and irinotecan. After 9 cycles, patients continued to receive maintenance treatment with Xeloda + Avastin. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: capecitabine [Xeloda] · Drug: bevacizumab [Avastin] · Drug: oxaliplatin
Drug: capecitabine [Xeloda] · Drug: bevacizumab [Avastin] · Drug: irinotecan
1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
5 mg/kg taken intravenously on Day 1 of each 2 week cycle
85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
Progression-free Survival (PFS) in U.S. Patients Only
PFS was defined as the time from the date of randomization to the first documented occurrence of disease progression or death due to any cause.
Time frame: From first patient enrolled up to approximately 48 months
| Milestone | XELOX + Bevacizumab (Q2W) | XELIRI + Bevacizumab (Q2W) |
|---|---|---|
| Started | 21 | 20 |
| Safety population | 19 | 20 |
| Completed | 0 | 2 |
| Not completed | 21 | 18 |
PFS was defined as the time from the date of randomization to the first documented occurrence of disease progression or death due to any cause.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XELOX + Bevacizumab (Q2W) | — | 4/19 (21.1%) | 17/19 (89.5%) |
| XELIRI + Bevacizumab (Q2W) | — | 7/20 (35%) | 19/20 (95%) |
| Event | XELOX + Bevacizumab (Q2W) | XELIRI + Bevacizumab (Q2W) |
|---|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/19 | 2/20 |
| Clostridium Difficile ColitisInfections and infestations | 1/19 | 0/20 |
| Hypertrophic CardiomyopathyCardiac disorders | 1/19 | 0/20 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/19 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 0/19 | 1/20 |
| Intestinal ObstructionGastrointestinal disorders | 0/19 | 1/20 |
| PneumoniaInfections and infestations | 0/19 | 1/20 |
| AstheniaGeneral disorders and administration site conditions | 0/19 | 1/20 |
| Lacunar InfarctionNervous system disorders | 0/19 | 1/20 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/19 | 1/20 |
| Event | XELOX + Bevacizumab (Q2W) | XELIRI + Bevacizumab (Q2W) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/19 | 11/20 |
| NauseaGastrointestinal disorders | 6/19 | 11/20 |
| Neuropathy PeripheralNervous system disorders | 9/19 | 0/20 |
| FatigueGeneral disorders and administration site conditions | 7/19 | 7/20 |
| Abdominal PainGastrointestinal disorders | 1/19 | 6/20 |
| AnorexiaMetabolism and nutrition disorders | 5/19 | 1/20 |
| VomitingGastrointestinal disorders | 4/19 | 5/20 |
| RashSkin and subcutaneous tissue disorders | 4/19 | 0/20 |
| ConstipationGastrointestinal disorders | 3/19 | 4/20 |
| DehydrationMetabolism and nutrition disorders | 3/19 | 4/20 |
| Age, Continuous(years) | XELOX + Bevacizumab (Q2W) | XELIRI + Bevacizumab (Q2W) | Total |
|---|---|---|---|
| Mean | 63.9 ± 12.06 | 60.6 ± 9.89 | 62.3 ± 11.04 |
| Sex: Female, Male(Participants) | XELOX + Bevacizumab (Q2W) | XELIRI + Bevacizumab (Q2W) | Total |
|---|---|---|---|
| Female | 8 | 7 | 15 |
| Male | 13 | 13 | 26 |
The record gives a start of May 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Irinotecan